Demand for minimally invasive breast cancer treatment was overarching theme of the conference In one independent study led by Professor Fukuma, 389 patients treated for up to 10 years had 99.74% recurrence free rate Another independent study led by Professor Kawamoto found 0% breast cancer local recurrence in five-year follow up ProSense® expected to gain further traction in Japan , as distribution partner Terumo Corporation plans to submit application to the Pharmaceuticals and Medical Devices Agency ("PMDA") for regulatory clearance for breast cancer in the first quarter of 2025 CAESAREA, Israel , July 22, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM ) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that key findings from three clinical studies of ProSense® in the treatment of breast cancer were presented at the 32nd Annual Meeting of the Japanese Breast Cancer Society on July 12, 2024 in Miyagi, Japan .
During a symposium titled, "New techniques and strategies in breast surgery", chaired by Professor Takayuki Kinoshita , Division of Breast Surgery, NHO Tokyo Medical Center, data on breast cancer cryoablation with ProSense® were presented by Prof. Eisuke Fukuma , Breast Center, Kameda Medical Center, and Prof. Hisanori Kawamoto , Department of Breast Surgery, Breast and Imaging Center at St.
Marianna University .